Bindu V Manyam1, Adam A Garsa2, Re-I Chin3, Chandana A Reddy1, Brian Gastman4, Wade Thorstad3, Sue S Yom2, Brian Nussenbaum5, Steven J Wang6, Allison T Vidimos7, Shlomo A Koyfman1. 1. Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio. 2. Department of Radiation Oncology, University of California San Francisco, San Francisco, California. 3. Department of Radiation Oncology, Washington University, St. Louis, Missouri. 4. Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio. 5. Department of Otolaryngology, Washington University, St. Louis, Missouri. 6. Department of Otolaryngology, University of California San Francisco, San Francisco, California. 7. Department of Dermatology, Cleveland Clinic, Cleveland, Ohio.
Abstract
BACKGROUND: Patients who are chronically immunosuppressed have higher rates of cutaneous squamous cell carcinoma of the head and neck (cSCC-HN). This is the largest multi-institutional study to date investigating the effect of immune status on disease outcomes in patients with cSCC-HN who underwent surgery and received postoperative radiation therapy (RT). METHODS: Patients from 3 institutions who underwent surgery and also received postoperative RT for primary or recurrent, stage I through IV cSCC-HN between 1995 and 2015 were included in this institutional review board-approved study. Patients categorized as immunosuppressed had chronic hematologic malignancy, human immunodeficiency/acquired immunodeficiency syndrome, or had received immunosuppressive therapy for organ transplantation ≥6 months before diagnosis. Overall survival, locoregional recurrence-free survival, and progression-free survival were calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed using Cox proportional-hazards regression. RESULTS: Of 205 patients, 138 (67.3%) were immunocompetent, and 67 (32.7%) were immunosuppressed. Locoregional recurrence-free survival (47.3% vs 86.1%; P < .0001) and progression-free survival (38.7% vs 71.6%; P = .002) were significantly lower in immunosuppressed patients at 2 years. The 2-year OS rate in immunosuppressed patients demonstrated a similar trend (60.9% vs 78.1%; P = .135) but did not meet significance. On multivariate analysis, immunosuppressed status (hazard ratio [HR], 3.79; P < .0001), recurrent disease (HR, 2.67; P = .001), poor differentiation (HR, 2.08; P = .006), and perineural invasion (HR, 2.05; P = .009) were significantly associated with locoregional recurrence. CONCLUSIONS: Immunosuppressed patients with cSCC-HN had dramatically lower outcomes compared with immunocompetent patients, despite receiving bimodality therapy. Immune status is a strong prognostic factor that should be accounted for in prognostic systems, treatment algorithms, and clinical trial design. Cancer 2017;123:2054-2060.
BACKGROUND:Patients who are chronically immunosuppressed have higher rates of cutaneous squamous cell carcinoma of the head and neck (cSCC-HN). This is the largest multi-institutional study to date investigating the effect of immune status on disease outcomes in patients with cSCC-HN who underwent surgery and received postoperative radiation therapy (RT). METHODS:Patients from 3 institutions who underwent surgery and also received postoperative RT for primary or recurrent, stage I through IV cSCC-HN between 1995 and 2015 were included in this institutional review board-approved study. Patients categorized as immunosuppressed had chronic hematologic malignancy, humanimmunodeficiency/acquired immunodeficiency syndrome, or had received immunosuppressive therapy for organ transplantation ≥6 months before diagnosis. Overall survival, locoregional recurrence-free survival, and progression-free survival were calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed using Cox proportional-hazards regression. RESULTS: Of 205 patients, 138 (67.3%) were immunocompetent, and 67 (32.7%) were immunosuppressed. Locoregional recurrence-free survival (47.3% vs 86.1%; P < .0001) and progression-free survival (38.7% vs 71.6%; P = .002) were significantly lower in immunosuppressed patients at 2 years. The 2-year OS rate in immunosuppressed patients demonstrated a similar trend (60.9% vs 78.1%; P = .135) but did not meet significance. On multivariate analysis, immunosuppressed status (hazard ratio [HR], 3.79; P < .0001), recurrent disease (HR, 2.67; P = .001), poor differentiation (HR, 2.08; P = .006), and perineural invasion (HR, 2.05; P = .009) were significantly associated with locoregional recurrence. CONCLUSIONS: Immunosuppressed patients with cSCC-HN had dramatically lower outcomes compared with immunocompetent patients, despite receiving bimodality therapy. Immune status is a strong prognostic factor that should be accounted for in prognostic systems, treatment algorithms, and clinical trial design. Cancer 2017;123:2054-2060.
Authors: Samantha Tam; Christopher M K L Yao; Moran Amit; Mona Gajera; Xiaoning Luo; Rachel Treistman; Anshu Khanna; Mohamed Aashiq; Priyadharsini Nagarajan; Diana Bell; Adel El-Naggar; Michael Migden; Michael Wong; Bonnie Glisson; Renata Ferrarotto; Bita Esmaeli; David Rosenthal; Guojun Li; Randal S Weber; Jeffrey N Myers; Neil D Gross Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-02-01 Impact factor: 6.223
Authors: Sofian Benkhaled; Dirk Van Gestel; Carolina Gomes da Silveira Cauduro; Samuel Palumbo; Veronique Del Marmol; Antoine Desmet Journal: Front Med (Lausanne) Date: 2022-06-27
Authors: Kristin Bibee; Andrew Swartz; Shaum Sridharan; Cornelius H L Kurten; Charles B Wessel; Heath Skinner; Dan P Zandberg Journal: Oral Oncol Date: 2020-02-14 Impact factor: 5.337
Authors: Flora Yan; Brittny N Tillman; Rajiv I Nijhawan; Divya Srivastava; David J Sher; Vladimir Avkshtol; Jade Homsi; Justin A Bishop; Erin M Wynings; Rebecca Lee; Larry L Myers; Andrew T Day Journal: Ann Surg Oncol Date: 2021-06-30 Impact factor: 5.344
Authors: Ioannis M Koukourakis; Axiotis G Giakzidis; Maria Kouroupi; Alexandra Giatromanolaki; Ioannis Abatzoglou; Antonios Karpouzis; Michael I Koukourakis Journal: BJR Case Rep Date: 2021-02-04
Authors: Timothy Budden; Caroline Gaudy-Marqueste; Sarah Craig; Yuan Hu; Charles H Earnshaw; Shilpa Gurung; Amelle Ra; Victoria Akhras; Patrick Shenjere; Ruth Green; Lynne Jamieson; John Lear; Luisa Motta; Carlos Caulín; Deemesh Oudit; Simon J Furney; Amaya Virós Journal: Clin Cancer Res Date: 2021-04-01 Impact factor: 13.801